JP2011505336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505336A5 JP2011505336A5 JP2010532071A JP2010532071A JP2011505336A5 JP 2011505336 A5 JP2011505336 A5 JP 2011505336A5 JP 2010532071 A JP2010532071 A JP 2010532071A JP 2010532071 A JP2010532071 A JP 2010532071A JP 2011505336 A5 JP2011505336 A5 JP 2011505336A5
- Authority
- JP
- Japan
- Prior art keywords
- azacytidine
- pharmaceutical composition
- composition according
- aza
- deoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98463807P | 2007-11-01 | 2007-11-01 | |
| US99278107P | 2007-12-06 | 2007-12-06 | |
| US3409308P | 2008-03-05 | 2008-03-05 | |
| US8606908P | 2008-08-04 | 2008-08-04 | |
| US9085208P | 2008-08-21 | 2008-08-21 | |
| PCT/US2008/012430 WO2009058394A1 (en) | 2007-11-01 | 2008-11-03 | Cytidine analogs for treatment of myelodysplastic syndromes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011505336A JP2011505336A (ja) | 2011-02-24 |
| JP2011505336A5 true JP2011505336A5 (https=) | 2011-12-22 |
Family
ID=40367738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532071A Pending JP2011505336A (ja) | 2007-11-01 | 2008-11-03 | 骨髄異形成症候群治療のためのシチジンアナログ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100311683A1 (https=) |
| EP (1) | EP2211870A1 (https=) |
| JP (1) | JP2011505336A (https=) |
| CA (1) | CA2742252A1 (https=) |
| WO (1) | WO2009058394A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| CA2545942C (en) | 2003-11-14 | 2012-07-10 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
| PL3692983T3 (pl) * | 2008-05-15 | 2021-12-27 | Celgene Corporation | Doustne formulacje analogów cytydyny i sposoby ich zastosowania |
| US8492361B2 (en) | 2009-02-10 | 2013-07-23 | Celgene Corporation | Methods for treating non-small cell lung cancer using 5-azacytidine |
| CN103619864A (zh) | 2011-03-31 | 2014-03-05 | 细胞基因国际有限公司 | 5-氮杂胞苷的合成 |
| WO2013022872A1 (en) * | 2011-08-10 | 2013-02-14 | Celgene Corporation | Gene methylation biomarkers and methods of use thereof |
| TW201700103A (zh) | 2011-11-01 | 2017-01-01 | 西建公司 | 利用胞嘧啶核苷類似物之口服配方治療癌症的方法 |
| KR101987861B1 (ko) | 2011-11-03 | 2019-06-11 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여 |
| US9493500B2 (en) * | 2012-07-19 | 2016-11-15 | Richard Daifuku | Fluorinated pyrimidine analogs and methods of use thereof |
| JP6431520B2 (ja) * | 2013-03-15 | 2018-11-28 | エピジェネティクス・ファーマ・エルエルシー | フッ化ピリミジン類縁体及びその使用方法 |
| WO2015051304A1 (en) | 2013-10-04 | 2015-04-09 | Aptose Biosciences Inc. | Compositions, biomarkers and their use in treatment of cancer |
| AU2015305449B2 (en) | 2014-08-22 | 2021-05-06 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| US20190054103A1 (en) * | 2016-02-26 | 2019-02-21 | Epigenetics Pharma, Llc | Method of treatment of tp53 wild-type tumors with 2',2'-difluoro-5-aza-2'-deoxycytidine or prodrugs thereof |
| WO2017189647A1 (en) * | 2016-04-26 | 2017-11-02 | Memorial Sloan Kettering Cancer Center | Methods and compositions for the treatment of myelodysplastic syndrome |
| WO2019089511A1 (en) | 2017-10-30 | 2019-05-09 | Aptose Biosciences Inc. | Aryl imidazoles for the treatment of cancer |
| GB201917899D0 (en) * | 2019-12-06 | 2020-01-22 | Nanexa Ab | New composition |
| WO2022093983A1 (en) * | 2020-10-27 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for treating hematopoietic malignancy |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641758A (en) * | 1993-11-10 | 1997-06-24 | Kluge; Michael | Cytarabine derivatives, the preparation and use thereof |
| US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
| CN1342146A (zh) * | 1999-03-18 | 2002-03-27 | 塞尔基因公司 | 取代的1－氧代－和1,3－二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途 |
| AU2001261474B2 (en) * | 2000-05-15 | 2006-03-09 | Celgene Corporation | Compositions and methods for the treatment of cancer |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| CN1668733A (zh) * | 2002-05-30 | 2005-09-14 | 细胞基因公司 | 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法 |
| CN1713905A (zh) * | 2002-10-15 | 2005-12-28 | 细胞基因公司 | 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药 |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20040162263A1 (en) * | 2002-10-31 | 2004-08-19 | Supergen, Inc., A Delaware Corporation | Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| US6887855B2 (en) * | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US6943249B2 (en) * | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US20080213213A1 (en) * | 2004-04-14 | 2008-09-04 | Zeldis Jerome B | Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione |
| AU2004319758A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| US20060128654A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| EP2043633B1 (en) * | 2006-07-18 | 2016-07-06 | University of Rochester | Thiadiazolidinone derivatives for treating cancer |
| JP5278968B2 (ja) * | 2006-08-30 | 2013-09-04 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法 |
| US20080057086A1 (en) * | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| PL3692983T3 (pl) * | 2008-05-15 | 2021-12-27 | Celgene Corporation | Doustne formulacje analogów cytydyny i sposoby ich zastosowania |
-
2008
- 2008-11-03 EP EP08845256A patent/EP2211870A1/en not_active Withdrawn
- 2008-11-03 CA CA2742252A patent/CA2742252A1/en not_active Abandoned
- 2008-11-03 JP JP2010532071A patent/JP2011505336A/ja active Pending
- 2008-11-03 WO PCT/US2008/012430 patent/WO2009058394A1/en not_active Ceased
- 2008-11-03 US US12/740,636 patent/US20100311683A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011505336A5 (https=) | ||
| JP2020094063A5 (https=) | ||
| Hu et al. | Increasing CCL5/CCR5 on CD4+ T cells in peripheral blood of oral lichen planus | |
| JP2018126141A5 (https=) | ||
| JP2008523157A5 (https=) | ||
| JP2011505336A (ja) | 骨髄異形成症候群治療のためのシチジンアナログ | |
| JP2012050438A5 (https=) | ||
| JP2019068829A5 (https=) | ||
| AR071808A1 (es) | Formulaciones orales de analogos de citidina, metodo de tratamiento, composicion farmaceutica y uso | |
| JP2012050439A5 (https=) | ||
| JP2014513954A5 (https=) | ||
| JP2016116520A5 (https=) | ||
| JP2006504745A5 (https=) | ||
| JP2004534769A5 (https=) | ||
| JP2012505660A5 (https=) | ||
| JP2017523777A5 (https=) | ||
| JP2010523156A5 (https=) | ||
| JP2015507625A5 (https=) | ||
| WO2013022872A1 (en) | Gene methylation biomarkers and methods of use thereof | |
| Parker et al. | 5-aza-4′-thio-2′-deoxycytidine, a new orally bioavailable nontoxic “Best-in-class”: DNA methyltransferase 1–depleting agent in clinical development | |
| JP2015504438A5 (https=) | ||
| JP2012522842A5 (https=) | ||
| Hui et al. | Epigenetic regulations in autoimmunity and cancer: from basic science to translational medicine | |
| JP2009506122A5 (https=) | ||
| WO2016201365A2 (en) | Methods for treating cancers |